DCPH - Is Deciphera Pharmaceuticals a Buy?
There are plenty of intriguing biotech stocks on the market right now, and many of them are trading at a steep discount due to the coronavirus pandemic. However, no matter how exciting a company's prospects might be, investors still need to do their due diligence before choosing to invest in any biotech stock.
Deciphera Pharmaceuticals (NASDAQ: DCPH) is one company on sale. Its lead drug candidate, ripretinib, is awaiting regulatory approval from the U.S. Food and Drug Administration (FDA) later this year. There's a lot of anticipation surrounding this decision; does this mean that now's a good time to buy this stock, or should you stay away from this company altogether?
Image source: Getty Images.